The World Healthscience Fund seeks to maximise total return and invest in a manner consistent with the principles of environmental, social and governance ("ESG") investing. The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.
AUM (million)
USD 12,480.62
FSM Risk Rating
10 - Highest Risk
Launch Date
05 Apr 2001
Launch Price
-
Historical Dividend
-
Dividend Yield (%)
-
Dividend Frequency
-
CPF Risk Classification
na
Min. Initial Amount
SGD 135.59 / USD 100.00
Min. RSP Investment
SGD 100.00
RSP Special List
Yes
Annual Expense Ratio
1.81%
LEARN MORE
Latest NAV Price
Past 3 Months
USD 78.29
USD 7.59
More
Annualised Returns
1 WK 4.050%
1 MTH 11.130%
3 MTH 8.020%
6 MTH 4.040%
YTD 4.040%
1 YR 16.550%
2 YR 4.750%
3 YR 6.800%
5 YR 3.750%
10 YR 8.480%
Calendar Year Returns
2025 13.086%
2024 1.936%
2023 2.183%
2022 -5.210%
2021 14.193%
Fund Historical Price
1Y High
78.29
02 Jul 2026
1Y Low
63.95
06 Aug 2025
3Y High
78.29
02 Jul 2026
3Y Low
59.36
29 Oct 2023
All Time High
78.29
02 Jul 2026
All Time Low
9.99
09 Aug 2004
Documents
Prospectus
02 Jul 2026
Semi-Annual Report
08 May 2026
Annual Report
28 Nov 2025
Product Highlights Sheet
27 Jun 2026
Fund Factsheet
24 Jun 2026
Funds Objective and Investment Information
Asset Class
Equity
Sector
Healthcare
Geographical Allocation
Global
RSP Special List
Yes
MAS Registration
Recognised
Right to cancel
No
Pricing Basis
Forward Pricing
Min. Initial Amount
SGD 135.59 / USD 100.00
Min. Subsequent Investment
SGD 135.59 / USD 100.00
Min. Redemption Amount
USD 100.00
Min. RSP Investment
SGD 100.00
Min. Holdings
USD 1,000.00
Charges & Fees
Yes
Dividend
No
Fund Manager Information
BlackRock is one of the world’s leading providers of investment, advisory and risk management solutions. BlackRock offers a range of solutions — from rigorous fundamental and quantitative active management approaches aimed at maximizing outperformance to highly efficient indexing strategies designed to gain broad exposure to the world's capital markets. Our clients can access our investment solutions through a variety of product structures, including individual and institutional separate accounts, mutual funds and other pooled investment vehicles, and the industry-leading iShares® ETFs.
Fund Top 10 Holdings(53.92% of Total Assets
18 Jun 2026)
All figures were extracted from the PDF, in the event of any discrepancies, please refer to the factsheet for confirmation.
Name
Weighting (%)
Sector
ELI LILLY
10.21
-
JOHNSON & JOHNSON
8.87
-
ASTRAZENECA PLC
5.49
-
UNITEDHEALTH GROUP INC
5.31
-
ROCHE PS PAR AG
4.70
-
NOVARTIS AG
4.47
-
MERCK & CO INC
4.23
-
ABBVIE INC
4.19
-
GILEAD SCIENCES INC
3.70
-
AMGEN INC
2.75
-
Country/Region
Last Updated on 18 Jun 2026
All figures were extracted from the PDF, in the event of any discrepancies, please refer to the factsheet for confirmation.
US
73.32%
Switzerland
11.59%
United Kingdom
6.89%
Germany
1.51%
Belgium
1.48%
Denmark
1.46%
Israel
1.37%
China
0.85%
Japan
0.81%
Others
1.41%
Sector
Last Updated on 18 Jun 2026
All figures were extracted from the PDF, in the event of any discrepancies, please refer to the factsheet for confirmation.
Pharmaceuticals
48.79%
Biotechnology
21.35%
Health Care Providers & Se...
11.00%
Health Care Equip. & Sup.
9.86%
Life Sciences Tools & Serv...
8.33%
Cash and/or Derivatives
0.66%
Payment Method
Included under CashYes
Included under SRSYes
Included under CPFIS-OANo
Included under CPFIS-SANo
Buy Processing Flow
Order Placement
05 Jul 2026
Order Transact
06 Jul 2026
Complete to Holdings
10 Jul 2026
Sell Processing Flow
Order Placement
05 Jul 2026
Order Transact
06 Jul 2026
Paid Out
15 Jul 2026
Risk Metric
3 YR Annualised Volatility
13.25%
3 YR Sharpe Ratio
0.35
1 YR Max Drawdown -10.55%
3 YR Max Drawdown -18.29%
Upcoming Fund HolidaysMORE
There are no upcoming fund holidays for this fund.
Tools
Fund Ideas
Fund Returns
Fund RSP
Fund Selector
Recommended Fund
Related Articles
FUND REVIEW BlackRock World Healthscience A2 USD
Tan Qiuyi Charmaine
21 Aug 2024 | 6230 views
MACRO RESEARCH After a disappointing 2023, will the global healthcare sector see a turnaround in 2024?
Chloe Nadia Halim
29 Jan 2024 | 2590 views
FUND REVIEW Blackrock World Healthscience A2 USD
iFAST Research Team
24 Aug 2023 | 2222 views
MACRO RESEARCH The US narrowly avoids a default, but what does it really mean for investors?
Yeo Hui Shi
13 Jun 2023 | 3792 views
For further assistance, please call our hotline at 6557 2853 from:
8:30am to 10:30pm, (Mondays to Fridays except PH) and
8:30am to 12:30pm, (Saturdays except PH)
@ 2026. All Rights Reserved. Reg. No. 200000231R S&P ratings, @ 2026, S&P Capital IQ (and its affiliates, as applicable). All Rights Reserved. Copyright @ 2026, American Bankers Association CUSIP Database provided by the S&P Capital IQ LLC. All rights reserved. Copyright @ 2026, Market data provided by Cboe One Real-Time Quote, Morningstar Research Pte. Ltd. & Morningstar Real-Time Data Ltd. All Rights Reserved. Copyright @ 2026, HKEX market data provided by HKEX Information Services Ltd. All Rights Reserved.
We use cookies
If you close this message or continue to use this site, you will consent to the use of Cookies, unless you choose to disable them. Click on our Privacy Policy to understand more.